<DOC>
	<DOCNO>NCT01565967</DOCNO>
	<brief_summary>The purpose study show success AutoLog System remove lipid le 10mg/dl vivo . The Autolog registry two objective : 1. determine lipid removal capability Medtronic AutoLog System . 2. obtain vivo data blood component removal wash capability Medtronic AutoLog System .</brief_summary>
	<brief_title>Registry AutoLog Lipid Removal Blood Component Characterization</brief_title>
	<detailed_description>Since house data strongly suggest Medtronic AutoLog uniquely high perform lipid removal in-vitro , Registry AutoLog Lipid Removal Blood Component Characterization initiate determine AutoLog system successful remove lipids vivo in-vitro . Therefore , expect lipid amount wash less 10 mg/dl . The study design multi-center , non-randomized , non-interventional , post market release study ( registry ) . The study single arm , without control , descriptive nature .</detailed_description>
	<criteria>Patients indication surgery procedures hospital treatment protocol require routine use autotransfusion system eligible participation . The use citratebased anticoagulant patient impair liver function Gross contamination and/or septic procedure Surgery within malignant area may allow dissemination tumor/malignant cell , aspirate , autotransfusion system Caesarean section presence amniotic fluid Presence high concentration prostatic fluid Contamination salvage blood drug intend intravenous administration Use collagenbased haemostatic agent gel foam use combination autotransfusion system Coagulopathy Not willing sign Patient Informed Consent/Data Release Form</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AutoLog</keyword>
	<keyword>Post market release</keyword>
	<keyword>Non-interventional</keyword>
</DOC>